Anti–vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD) has been a resounding success and a breakthrough in the treatment for a disease complication that can devastate lives. As a group, patients do very well, at least for the first few years, if treated sufficiently often to control neovascular activity. However, even when treatments are delivered with appropriate, protocol-directed treatment frequencies, with time, atrophy and fibrosis affect the outcomes and can be associated with loss of visual acuity.1 Understanding the drivers and risk factors for the development of these late complications, which can limit visual acuity outcomes despite successful suppression of the VEGF drive, is critical if we are to limit their effects in an attempt to maintain early visual acuity gains in the long term.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Guymer RH. Treating Neovascular Age-Related Macular Degeneration—So Much More to Learn. JAMA Ophthalmol. 2020;138(10):1051–1052. doi:10.1001/jamaophthalmol.2020.3000
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: